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Abstract
Background: Two genome‐wide association studies in European and Japanese pop-
ulations reported on new loci for diabetic kidney disease (DKD), including FTO. In 
this study, we have replicated these investigations on a cohort of 410 Type 2 diabetes 
mellitus (T2DM) patients of Arab origin from the United Arab Emirates (UAE).
Methods and Results: The cohort included 145 diabetic patients diagnosed with DKD 
and 265 diabetics free of the disease. In general, we were able to confirm the association 
between the FTO locus and DKD, as reported in the Japanese population. Specifically, 
there were significant associations with two single nucleotide polymorphisms (SNPs), 
namely rs1421086 (p = .013, OR = 1.52 depending on allele G, 95% CI: 1.09–2.11) and 
rs17817449 (p = .0088, OR = 1.55 depending on allele C, 95% CI: 1.12–2.14) of the FTO 
locus. Both SNPs were in linkage disequilibrium with rs56094641, also as reported in the 
Japanese population. While the alleles of both SNPs, which increase the risk of DKD, 
were associated with higher Body Mass Index (BMI), their associations with DKD were 
independent of the BMI effects.
Conclusions: This study confirms that FTO is a multiethnic locus for DKD which is 
independent from any influence of BMI and/or obesity.
K E Y W O R D S
diabetic kidney disease, FTO, genetics, Type 2 diabetes, United Arab Emirates
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1 |  INTRODUCTION
Diabetic kidney disease (DKD) is a common complication 
of both Type 1 and Type 2 diabetes mellitus (T2DM). In pa-
tients with T2DM, the risk of DKD is approximately 2% per 
year of the disease (Gross et al., 2005). The prevalence of 
DKD in patients with T2DM is variable depending on several 
factors, including ethnicity (Thomas et al., 2015). The preva-
lence of DKD in Arab populations is also variable and ranges 
from 10.8% to 61.2% (Aldukhayel, 2017); being reported as 
~6% in the United Arab Emirates (UAE) among patients with 
T2DM (Jelinek et al., 2017).
We have recently reported that the duration of the T2DM 
was the most significant risk factor related to the develop-
ment of DKD in the Arab population of the UAE (Osman, 
Jelinek, et al., 2018). We have also confirmed that among the 
43 genetic loci linked to DKD and included in the study, the 
SHROOM3 locus was the only locus with associations with 
DKD patients from UAE (Osman, Jelinek, et al., 2018).
Recently, two genome‐wide association studies in a 
Japanese population (Taira et al., 2018) and a European pop-
ulation (van Zuydam et al., 2018) reported associations with 
new genetic loci for DKD. Among these, significant associ-
ations were reported with GABRR1, UMOD, and PRKAG2 
in Europeans (van Zuydam et al., 2018) and with FTO in the 
Japanese cohort (Taira et al., 2018), in addition to additional 
six highly suggestive associations in the Japanese popula-
tion. These loci have not been considered in individuals of 
Arabian ancestry. Therefore, our aim was to investigate the 
associations of these newly reported loci in the UAE Arab 
population.
2 |  METHODS
2.1 | Ethical compliance
Each patient agreed to take part in this study and provided 
an informed signed consent after a brief session to ex-
plain the aims and methods. The study was approved by 
the Institutional Ethics Committees of Mafraq and Sheikh 
Khalifa Medical Centre hospitals (REC‐04062014 and R292, 
respectively) and conformed to the ethical principles outlined 
in the Helsinki declaration.
2.2 | Patients and demographic data
This report describes a cross‐sectional study of Emirati patients 
from the city of Abu Dhabi. The details regarding the T2DM 
patients, their demographic information, clinical data, and 
DKD characterization are all summarized in our previous re-
port (Osman, Jelinek, et al., 2018). Participants were recruited 
from Mafraq and Sheikh Khalifa Medical City Hospitals, Abu 
Dhabi, UAE. In total, 145 T2DM patients with DKD and 265 
without DKD met the criteria for inclusion in this study. The 
demographic data are shown in Table 1.
2.3 | Patient and public involvement
The study was designed as a follow‐up for our previous 
study in DKD in the UAE, which constitutes a major health 
problem. However, patients and the public at large were not 
involved in defining the research questions, analyses, inter-
pretation, or dissemination of the results.
2.4 | Selection of SNPs
Single nucleotide polymorphisms (SNPs) summarized in 
Table 2 were selected based on the results of the previous 
two genome‐wide studies for DKD (Taira et al., 2018; van 
Zuydam et al., 2018). For the SNPs which were not avail-
able for analysis in our T2DM cohort (Alsafar, Jama‐Alol, 
Hassoun, & Tay, 2012), we selected proxy SNPs depending 
on their Linkage Disequilibrium (r2 >  .8) with the original 
index SNPs using data from the European samples collected 
in phase 3 of the 1,000 genome project and stored in the 
rAggr database (http://raggr.usc.edu/), as a reference. For the 
FTO rs56094641, we included two proxies; rs1421085 which 
is the strongest linked SNP in our database, and rs17817449 
because it was reported to be associated with end‐stage renal 
disease (ESRD) by Hubacek et al. (2011).
2.5 | Statistical analyses
PLINK software version 1.07 (http://zzz.bwh.harva rd.edu/
plink/ ) was used for counting allele frequencies and test-
ing the quality control (QC) variables, including Hardy–
Weinberg equilibrium. The same software was also used for 
testing the associations between the SNPs and DKD using 
a logistic regression model with assumption of additive ef-
fect. The model included age, gender, log Body Mass Index 
(BMI), and T2DM duration as covariates, as previously re-
ported, to avoid bias (Taira et al., 2018; van Zuydam et al., 
2018). The results are presented as p‐values and odds ratios 
with corresponding 95% confidence intervals. As this was a 
T A B L E  1  Demographic data of 410 participants
Variable DKD No DKD pa
Gender: Female 70 (48.3%) 165 (62.3%) .006
Age (years) 67.0 ± 10.4 58.6 ± 10.6 <.0001
Diabetes duration 
(years)
16.0 ± 9.2 10.1 ± 7.3 <.0001
BMI (kg/m2) 31.3 ± 6.0 32.5 ± 6.3 .078
Abbreviation: DKD, diabetic kidney disease.
ap‐value for continuous data, calculated using two‐sided t‐test and for percentage 
data calculated using Pearson chi‐squared test. 
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replication study, p <  .05 were considered as a replication. 
However, considering the Bonferroni correction for multiple 
testing, the p‐values are statistically significant at p <  .005 
(0.05/10).
2.6 | Statistical power considerations
Power calculations were done based on the current sample size 
(145 patients with T2DM and DKD vs. 265 patients with T2DM 
but without DKD), prevalence of DKD in the UAE population 
~6% (Jelinek et al., 2017), genotype risk for each SNP, as re-
ported previously (Taira et al., 2018; van Zuydam et al., 2018), 
significance level of 0.05 (assuming testing individual mark-
ers separately), disease allele frequency for each tested SNP, as 
reported in this study, and multiplicative model. Full details of 
power calculations are shown in Table S1. Accordingly, power 
of different SNPs, in this study, ranged from ~13% to 37%. 
These power calculations were performed using the Genetic 
Association Study Power Calculator (http://csg.sph.umich.
edu//abeca sis/cats/gas_power_calcu lator/ index.html).
3 |  RESULTS
Nine genetic loci were included in the analysis. These include 
three loci which were previously reported in the European 
population (van Zuydam et al., 2018), in addition to six re-
ported in the Japanese population (Taira et al., 2018). The SNP 
rs13306536 in LRP8 is not polymorphic in the UAE population 
(Table 2). Following adjustment of covariates (see Methods 
Section), two SNPs in FTO showed significant associations 
with DKD; namely, rs1421086 (p = .013, OR = 1.52 depend-
ing on allele G, 95% CI: 1.09–2.11) and rs17817449 (p = .0088, 
OR = 1.54 depending on allele C, 95% CI: 1.12–2.14), Table 3. 
The SNP rs1421086 was included in this analysis as the best 
proxy for rs56094641 in our database (r2 = .98, D’ = 1), and 
rs17817449 was included because it is both highly linked to 
rs56094641 and reported to be associated with end‐stage renal 
disease (ESRD) (Hubacek et al., 2011). The association results 
of both SNPs remained significant without adjustment for BMI; 
rs1421085 (p = .014, OR = 1.51 depending on allele C, 95% 
CI: 1.09–2.1) and rs17817449 (p = .013, OR = 1.51 depending 
on allele C, 95% CI: 1.09–2.08).
4 |  DISCUSSION
Diabetes Kidney Disease is a leading cause of ESRD. In 
the Arabian peninsula, DKD is responsible for approxi-
mately 17% of ESRD cases (Hassanien, Al‐Shaikh, Vamos, 
Yadegarfar, & Majeed, 2012). Genetic factors are expected 
to influence the development of DKD, as the disease tends 
to have a familial clustering (Fava, Azzopardi, Hattersley, & 
Watkins, 2000; Krolewski, 1999). Since the UAE has one of 
the highest incidences of T2DM (Alsafar et al., 2012) and 
diabetes complications (Jelinek et al., 2017) in the world, it 
is important to understand the pathophysiological factors un-
derlining these conditions, including genetic factors.
Few studies with solid associations have been reported in 
the Literature. However, in 2018, two genome‐wide studies 
with a significant number of patients were published (Taira 
et al., 2018; van Zuydam et al., 2018). This study aimed to 
replicate these works, although in the current report, only one 
locus, FTO, was investigated. Some risk alleles for DKD, such 
as rs1421085 (p = .07, coefficient = 0.01) and rs17817449 
(p  =  .0034, coefficient  =  0.016), also tend to have higher 
BMI following adjustment for age and gender. However, the 
associations of both rs1421085 and rs17817449 with DKD 
T A B L E  2  SNPs tested in this study and selection of proxy SNPs for missing index SNPs
Original SNP Chr Gene OMIN accession no Tested SNP r2 D’ Distancea
rs9942471 6 GABRR1 * 137,161 rs1186903 0.95 1 20.661
rs11864909 16 UMOD * 191,845 Index      
rs10224002 7 PRKAG2 * 602,743 rs7805747 0.88 0.96 7.240
rs56094641 16 FTO * 610,966 rs1421085 0.98 1 5.499
rs56094641 16 FTO * 610,966 rs17817449 0.92 1 −6.914
rs895157 17 PRCD * 610,598 rs752049 0.81 1 −6.022
rs10144968 14 RAD51B * 602,948 rs6573851 0.99 1 1.023
rs7544082 1 TRABD2B * 614,913 Index — — —
rs11101179 10 CHAT * 118,490 Index — — —
rs710375 5 CCNH‐TMEM161B * 601953‐ #613443 Index — — —
rs13306536 1 LRP8 * 602,600 Not a SNP in UAE 
population
— — —
Abbreviation: Chr, chromosome.
aDistance between proxy and original SNPs in kilo base pair. 
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were independent of the BMI values in the current study. This 
is in line with the results of Taira et al. (2018). These results 
suggest that FTO seems to influence DKD through a mech-
anism other than obesity, which is a known risk factor for 
chronic kidney disease (Wickman & Kramer, 2013). In fact, 
both SNPs also remained associated with DKD even follow-
ing adjustment for hypertension and estimated Glomerular 
Filtration Rate (data not shown).
The risk allele frequency of both SNPs, and hence 
rs56094641, is high in the UAE Arab population in comparison 
with the Japanese population, ranging from 0.4 to 0.42, which is 
similar to some European populations (see NCBI database). In 
this sense, obesity rates in the UAE are also high (Katsaiti & El 
Anshasy, 2013), and FTO is consistently associated with obe-
sity in the UAE population (Khan, Chehadeh, Abdulrahman, 
Osman, & Al Safar, 2018; Osman, Tay, & Alsafar, 2018).
Finally, in spite of the fact that this study had a relatively 
small sample size and a study power ~30% of FTO SNPs, 
the association of FTO with DKD was validated using two 
separate SNPs in individuals of Arab origin. A limitation for 
to this study was that the analyses carried out did not include 
treatment modalities due to patients having multiple condi-
tions and treatments, which made the models unstable and 
difficult to interpret.
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